C.D. DiNardo, B.A. Jonas, V. Pullarkat, et al., Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617–629 (2020)

Article  CAS  PubMed  Google Scholar 

S.L. Maude, T.W. Laetsch, J. Buechner, et al., Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S.S. Neelapu, F.L. Locke, N.L. Bartlett, et al., Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

P.G. Coulie, B.J. Van den Eynde, P. van der Bruggen, T. Boon, Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14, 135–146 (2014)

Article  CAS  PubMed  Google Scholar 

S. Srivastava, S.R. Riddell, Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J. Immunol. 200, 459–468 (2018)

Article  CAS  PubMed  Google Scholar 

G. Xie, N.A. Ivica, B. Jia, et al., CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nat. Biomed. Eng. 5, 399–413 (2021)

Article  CAS  PubMed  Google Scholar 

G. Ciotti, G. Marconi, A. Sperotto, M.B. Giannini, M. Gottardi, G. Martinelli, Biological therapy in elderly patients with acute myeloid leukemia. Expert Opin. Biol. Ther. 23, 175–194 (2023)

Article  CAS  PubMed  Google Scholar 

P.F. Bross, J. Beitz, G. Chen, et al., Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490–1496 (2001)

CAS  PubMed  Google Scholar 

C.D. Godwin, R.P. Gale, R.B. Walter, Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia 31, 1855–1868 (2017)

Article  CAS  PubMed  Google Scholar 

A.A. Laing, C.J. Harrison, B.E.S. Gibson, K. Keeshan, Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia. Exp. Hematol. 54, 40–50 (2017)

Article  CAS  PubMed  Google Scholar 

G.S. Laszlo, E.H. Estey, R.B. Walter, The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood. Rev. 28, 143–153 (2014)

Article  CAS  PubMed  Google Scholar 

R.A. Gardner, O. Finney, C. Annesley, et al., Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322–3331 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Ruella, D.M. Barrett, S.S. Kenderian, et al., Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J. Clin. Invest. 126, 3814–3826 (2016)

Article  PubMed  PubMed Central  Google Scholar 

R.M. Myers, A. Taraseviciute, S.M. Steinberg, et al., Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J. Clin. Oncol. 40, 932–944 (2022)

Article  CAS  PubMed  Google Scholar 

L. Labanieh, C.L. Mackall, CAR immune cells: design principles, resistance and the next generation. Nature 614, 635–648 (2023)

Article  CAS  PubMed  Google Scholar 

Y. Liu, S. Wang, M.L. Schubert, et al., CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int. J. Cancer 150, 1141–1155 (2022)

Article  CAS  PubMed  Google Scholar 

Q.S. Wang, Y. Wang, H.Y. Lv, et al., Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol. Ther. 23, 184–191 (2015)

Article  CAS  PubMed  Google Scholar 

I.D. Bernstein, J.W. Singer, F.O. Smith, et al., Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood 79, 1811–1816 (1992)

Article  CAS  PubMed  Google Scholar 

R.B. Walter, F.R. Appelbaum, E.H. Estey, I.D. Bernstein, Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119, 6198–6208 (2012)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Y. Xu, J. Mou, Y. Wang, et al., Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway. Leukemia 36, 403–415 (2022)

Article  CAS  PubMed  Google Scholar 

N. Chen, Y. Xu, J. Mou, et al., Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood Cancer J. 11, 144 (2021)

Article  PubMed  PubMed Central  Google Scholar 

G.S. Laszlo, C.J. Gudgeon, K.H. Harrington, et al., Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 123, 554–561 (2014)

Article  CAS  PubMed  PubMed Central  Google Scholar 

T. Zhang, M.L. Chen, X.Y. Liu, et al., [Preparation of CD33 targeted bispecific- and trispecific-T cell engagers and their cytotoxicity on leukemia cells]. Zhonghua Xue Ye Xue Za Zhi 43, 376–382 (2022)

CAS  PubMed  Google Scholar 

T.L. Arvedson, M. Balazs, P. Bogner, et al., Abstract 55: generation of half-life extended anti-CD33 BiTE® antibody constructs compatible with once-weekly dosing. Cancer Res. 77, 55–55 (2017)

Article  Google Scholar 

D.M. Barrett, N. Singh, D.L. Porter, S.A. Grupp, C.H. June, Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65, 333–347 (2014)

Article  CAS  PubMed  Google Scholar 

U. Brinkmann, R.E. Kontermann, The making of bispecific antibodies. MAbs 9, 182–212 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

L. Alvarez-Vallina, Genetic approaches for antigen-selective cell therapy. Curr. Gene Ther. 1, 385–397 (2001)

Article  CAS  PubMed  Google Scholar 

B. Blanco, P. Holliger, R.G. Vile, L. Alvarez-Vallina, Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J. Immunol. 171, 1070–1077 (2003)

Article  CAS  PubMed  Google Scholar 

B.D. Choi, X. Yu, A.P. Castano, et al., CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049–1058 (2019)

Article  CAS  PubMed  Google Scholar 

A.J. Davenport, R.S. Cross, K.A. Watson, et al., Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 115, E2068–e2076 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.Y. Kim, K.R. Yu, S.S. Kenderian, et al., Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloi